Critical Therapeutics raising $54M

Critical Therapeutics of Lexington, Massachusetts, plans to raise $54.5 million in a private stock sale with a part of the funds going to relaunch its Zyflo asthma drug, acquired from Abbott last year. The launch is expected in the second half of this year. Other funds will go to advance its pipeline drugs.

- read this story from the AP for more

Suggested Articles

A phase 3 study of NuCana’s lead drug was halted because a monitoring committee deemed it unlikely to succeed.

The filing follows data from Japanese phase 3 trials that assessed the oral HIF-PHI in chronic kidney disease patients.

The Allen Institute found major differences in human and mouse brain cells, which could guide the design of drugs for brain diseases.